Maintaining cognitive brain health is a high priority for both people with Parkinson’s disease (PD) and family members. Though many living with Parkinson’s will not develop dementia, mild cognitive issues may emerge in 20 to 50 percent.
What's Hot in PD?
We always advise patients to ask their doctor what’s new in Parkinson’s disease (PD). Recently, three leading experts at the Parkinson’s Foundation Center Leadership Conference reviewed the field and updated all attendees on several of the exciting therapies currently being tested by Albert Hung, MD, PhD, Massachusetts General Hospital (MGH); Irene Richard, MD, University of Rochester Medical Center; and Hubert Fernandez, MD, Cleveland Clinic.
A recent study by Inga and colleagues at the Mount Sinai Beth Israel Parkinson’s Foundation Center of Excellence in New York examined the incidence of Parkinson’s disease in inflammatory bowel disease patients.
The recent forecasting estimates for Parkinson’s disease (PD) are staggering. If accurate, the numbers suggest an urgent need to wake up and recognize that we are on the cusp of an emerging pandemic (Okun, 2013).
Parkinson’s disease (PD) specialists have long debated the potential value of Parkinson’s-specific physical therapy. All great medical debates are usually settled by two factors: time and data. In this month’s What’s Hot, we review a paper recently published in Lancet Neurology (Ypinga 2018) that provides insight and data for whether people with Parkinson’s should begin or continue specialized physiotherapy.
Many people with Parkinson’s disease (PD) struggle with gastrointestinal issues. More specifically, the movements of the digestive system (known as gastrointestinal motility).
Mucuna pruriens variant utilis (MP) has long been used as an alternative to over the counter levodopa. MP is a leguminous plant that grows in both tropical and subtropical environments. Hidden in its seed is levodopa, which is the most important medication for a Parkinson’s disease patient. In this month’s What’s Hot we will review the studies supporting MP use and discuss future directions and global implications for this therapy.
Should we consider subcutaneous apomorphine infusions for Parkinson’s disease patients who do not want deep brain stimulation or a A chemical messenger (neurotransmitter) that regulates movement and emotions. pump? There is a growing interest among people with Parkinson’s disease (PD) and families for a “nonsurgical” alternative to
Safinamide (Xadago) was approved by the Food and Drug Administration (FDA) for treatment of Parkinson’s disease (PD) medication fluctuations. Safinamide is a pill that when absorbed in the bloodstream travels to the brain and affects dopaminergic and non-dopaminergic systems.
Hope is something that is critical for everyone living with Parkinson’s disease. Hope for improvement in symptoms. Hope for a better life. Hope for a treatment that may one day arrest disease progression or even deliver a cure. We should embrace hope, but we should also protect everyone living with Parkinson’s disease and their family members from emotionally as well as financially draining opportunities which may overpromise and under-deliver.